Genomic biomarkers for breast cancer risk

Michael F. Walsh, Katherine L. Nathanson, Fergus J Couch, Kenneth Offit

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

Clinical risk assessment for cancer predisposition includes a three-generation pedigree and physical examination to identify inherited syndromes. Additionally genetic and genomic biomarkers may identify individuals with a constitutional basis for their disease that may not be evident clinically. Genomic biomarker testing may detect molecular variations in single genes, panels of genes, or entire genomes. The strength of evidence for the association of a genomic biomarker with disease risk may be weak or strong. The factors contributing to clinical validity and utility of genomic biomarkers include functional laboratory analyses and genetic epidemiologic evidence. Genomic biomarkers may be further classified as low, moderate or highly penetrant based on the likelihood of disease. Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes. When applied in the context of appropriate counseling and interpretation, identification of genomic biomarkers of inherited risk for breast cancer may decrease morbidity and mortality, allow for definitive prevention through assisted reproduction, and serve as a guide to targeted therapy.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages1-32
Number of pages32
Volume882
DOIs
StatePublished - 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume882
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Biomarkers
Breast Neoplasms
Genes
Mutation
Pedigree
Polymorphism
Risk assessment
Physical Examination
Single Nucleotide Polymorphism
Reproduction
Counseling
Nucleotides
Association reactions
Genome
Morbidity
Mortality
Testing
Neoplasms

Keywords

  • Biomarkers
  • BRCA
  • Breast oncology
  • Chemoprevention
  • Genetic counseling
  • Genetic testing
  • Genetics
  • Genomics
  • Prophylactic

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Walsh, M. F., Nathanson, K. L., Couch, F. J., & Offit, K. (2016). Genomic biomarkers for breast cancer risk. In Advances in Experimental Medicine and Biology (Vol. 882, pp. 1-32). (Advances in Experimental Medicine and Biology; Vol. 882). Springer New York LLC. https://doi.org/10.1007/978-3-319-22909-6_1

Genomic biomarkers for breast cancer risk. / Walsh, Michael F.; Nathanson, Katherine L.; Couch, Fergus J; Offit, Kenneth.

Advances in Experimental Medicine and Biology. Vol. 882 Springer New York LLC, 2016. p. 1-32 (Advances in Experimental Medicine and Biology; Vol. 882).

Research output: Chapter in Book/Report/Conference proceedingChapter

Walsh, MF, Nathanson, KL, Couch, FJ & Offit, K 2016, Genomic biomarkers for breast cancer risk. in Advances in Experimental Medicine and Biology. vol. 882, Advances in Experimental Medicine and Biology, vol. 882, Springer New York LLC, pp. 1-32. https://doi.org/10.1007/978-3-319-22909-6_1
Walsh MF, Nathanson KL, Couch FJ, Offit K. Genomic biomarkers for breast cancer risk. In Advances in Experimental Medicine and Biology. Vol. 882. Springer New York LLC. 2016. p. 1-32. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-22909-6_1
Walsh, Michael F. ; Nathanson, Katherine L. ; Couch, Fergus J ; Offit, Kenneth. / Genomic biomarkers for breast cancer risk. Advances in Experimental Medicine and Biology. Vol. 882 Springer New York LLC, 2016. pp. 1-32 (Advances in Experimental Medicine and Biology).
@inbook{b8754143af84402a9b64ed9671caf33c,
title = "Genomic biomarkers for breast cancer risk",
abstract = "Clinical risk assessment for cancer predisposition includes a three-generation pedigree and physical examination to identify inherited syndromes. Additionally genetic and genomic biomarkers may identify individuals with a constitutional basis for their disease that may not be evident clinically. Genomic biomarker testing may detect molecular variations in single genes, panels of genes, or entire genomes. The strength of evidence for the association of a genomic biomarker with disease risk may be weak or strong. The factors contributing to clinical validity and utility of genomic biomarkers include functional laboratory analyses and genetic epidemiologic evidence. Genomic biomarkers may be further classified as low, moderate or highly penetrant based on the likelihood of disease. Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes. When applied in the context of appropriate counseling and interpretation, identification of genomic biomarkers of inherited risk for breast cancer may decrease morbidity and mortality, allow for definitive prevention through assisted reproduction, and serve as a guide to targeted therapy.",
keywords = "Biomarkers, BRCA, Breast oncology, Chemoprevention, Genetic counseling, Genetic testing, Genetics, Genomics, Prophylactic",
author = "Walsh, {Michael F.} and Nathanson, {Katherine L.} and Couch, {Fergus J} and Kenneth Offit",
year = "2016",
doi = "10.1007/978-3-319-22909-6_1",
language = "English (US)",
volume = "882",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "1--32",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Genomic biomarkers for breast cancer risk

AU - Walsh, Michael F.

AU - Nathanson, Katherine L.

AU - Couch, Fergus J

AU - Offit, Kenneth

PY - 2016

Y1 - 2016

N2 - Clinical risk assessment for cancer predisposition includes a three-generation pedigree and physical examination to identify inherited syndromes. Additionally genetic and genomic biomarkers may identify individuals with a constitutional basis for their disease that may not be evident clinically. Genomic biomarker testing may detect molecular variations in single genes, panels of genes, or entire genomes. The strength of evidence for the association of a genomic biomarker with disease risk may be weak or strong. The factors contributing to clinical validity and utility of genomic biomarkers include functional laboratory analyses and genetic epidemiologic evidence. Genomic biomarkers may be further classified as low, moderate or highly penetrant based on the likelihood of disease. Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes. When applied in the context of appropriate counseling and interpretation, identification of genomic biomarkers of inherited risk for breast cancer may decrease morbidity and mortality, allow for definitive prevention through assisted reproduction, and serve as a guide to targeted therapy.

AB - Clinical risk assessment for cancer predisposition includes a three-generation pedigree and physical examination to identify inherited syndromes. Additionally genetic and genomic biomarkers may identify individuals with a constitutional basis for their disease that may not be evident clinically. Genomic biomarker testing may detect molecular variations in single genes, panels of genes, or entire genomes. The strength of evidence for the association of a genomic biomarker with disease risk may be weak or strong. The factors contributing to clinical validity and utility of genomic biomarkers include functional laboratory analyses and genetic epidemiologic evidence. Genomic biomarkers may be further classified as low, moderate or highly penetrant based on the likelihood of disease. Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes. When applied in the context of appropriate counseling and interpretation, identification of genomic biomarkers of inherited risk for breast cancer may decrease morbidity and mortality, allow for definitive prevention through assisted reproduction, and serve as a guide to targeted therapy.

KW - Biomarkers

KW - BRCA

KW - Breast oncology

KW - Chemoprevention

KW - Genetic counseling

KW - Genetic testing

KW - Genetics

KW - Genomics

KW - Prophylactic

UR - http://www.scopus.com/inward/record.url?scp=84961626046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961626046&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-22909-6_1

DO - 10.1007/978-3-319-22909-6_1

M3 - Chapter

VL - 882

T3 - Advances in Experimental Medicine and Biology

SP - 1

EP - 32

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -